BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) CEO Sells $ 496,260.00 in Shares

0


CEO of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Jean Jacques Bienaime sold 6,000 shares of the company in a transaction that took place on Wednesday, December 15. The stock was sold for an average price of $ 82.71, for a total value of $ 496,260.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jean Jacques Bienaime has also recently done the following job (s):

  • On Wednesday December 1, Jean Jacques Bienaime sold 1,500 BioMarin Pharmaceutical shares. The stock was sold for an average price of $ 87.22, for a total value of $ 130,830.00.

The NASDAQ BMRN traded at $ 2.89 on Friday, reaching $ 86.48. 2,222,153 shares were traded, for an average volume of 1,209,715. BioMarin Pharmaceutical Inc. has a 52-week low of $ 71.59 and a 52-week high of $ 92.31. The company has a debt to equity ratio of 0.25, a current ratio of 4.49, and a rapid ratio of 3.03. The company has a market cap of $ 15.88 billion, a price / earnings ratio of 1,081.00, a P / E / G ratio of 8.97 and a beta of 0.49. The company’s 50-day mobile average price is $ 82.06 and its two-hundred-day mobile average price is $ 80.40.

BioMarin Pharmaceutical (NASDAQ: BMRN) last released its quarterly earnings data on Tuesday, October 26. The biotech company reported ($ 0.20) earnings per share for the quarter, beating the consensus estimate of ($ 0.25) by $ 0.05. BioMarin Pharmaceutical had a net margin of 0.86% and a return on equity of 2.02%. The company posted revenue of $ 408.74 million for the quarter, compared to $ 435.29 million expected by analysts. During the same period of the previous year, the company posted $ 0.29 in EPS. The company’s quarterly revenue is down 14.3% from the same quarter last year. Stock analysts predict that BioMarin Pharmaceutical Inc. will post 0.29 EPS for the current fiscal year.

(A d)

It could be the highest grossing event in crypto history. And that only happens once. If you miss it, there is no second chance.

A number of hedge funds and other institutional investors have recently bought and sold shares of BMRN. Lake Point Wealth Management purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $ 33,000. Ancora Advisors LLC increased its stake in BioMarin Pharmaceutical shares by 466.7% during the 3rd quarter. Ancora Advisors LLC now owns 425 shares of the biotech company valued at $ 33,000 after acquiring 350 additional shares in the last quarter. Itau Unibanco Holding SA acquired a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $ 34,000. Liberty Wealth Management LLC increased its stake in BioMarin Pharmaceutical shares by 181.7% during the 3rd quarter. Liberty Wealth Management LLC now owns 431 shares of the biotech company valued at $ 34,000 after acquiring an additional 278 shares in the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of BioMarin Pharmaceutical during the second quarter valued at $ 41,000. Hedge funds and other institutional investors hold 94.28% of the company’s shares.

Several equity research analysts recently commented on BMRN stocks. Guggenheim raised its price target for BioMarin Pharmaceutical from $ 103.00 to $ 120.00 and gave the stock a “buy” rating in a report released on Monday, November 22. William Blair upgraded BioMarin Pharmaceutical from a “market performance” rating to an “outperformance” rating in a report released on Monday, November 22. The Royal Bank of Canada reissued a “custody” rating and set a target price of $ 88.00 for shares of BioMarin Pharmaceutical in a report released on Tuesday, September 7. Wedbush reissued an “outperformance” rating and set a target price of $ 152.00 for shares of BioMarin Pharmaceutical in a report released on Thursday, October 28. Finally, Piper Sandler raised her price target on BioMarin Pharmaceutical from $ 119.00 to $ 121.00 and rated the stock “overweight” in a report released Thursday, October 28. Four analysts gave the stock a conservation rating and twelve gave the company a buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $ 107.53.

About BioMarin Pharmaceutique

BioMarin Pharmaceutical, Inc is committed to the development and commercialization of therapies for people with rare diseases and serious and life-threatening medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide and BMN 307. The company was founded by John C. Klock, Christopher M.

Feature article: Institutional investors

Insider buy and sell by quarter for BioMarin Pharmaceutical (NASDAQ: BMRN)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in BioMarin Pharmaceutical now?

Before you consider BioMarin Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly asking their clients to buy now before the wider market takes hold of … and BioMarin Pharmaceutical was not on the list.

Although BioMarin Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Share.

Comments are closed.